ATOS

News Are Medical Stocks Lagging Alvotech (ALVO) This Year?

14d ago

News Atossa Therapeutics GAAP EPS of -$1.11

25d ago

SEC filing ATOS Settles Endoxifen Patent Dispute with Intas, Jina; Preserves Z-Endoxifen Development Rights, PTAB Termination Expected

47d ago

SEC filing ATOS Reports $0 Revenue, -$0.08 EPS, FDA Rare Pediatric & Orphan Designations for (Z)-Endoxifen in DMD, 2025 Clinical Trials Arena Award

69d ago

SEC filing ATOS Highlights 2025 Progress in Oncology Trials, Pauses Metastatic Breast Cancer Study, Explores Duchenne Muscular Dystrophy Potential

111d ago

News Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

132d ago

News Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

137d ago

News Atossa Therapeutics shares rise after FDA grants orphan drug designation for soft tissue sarcoma

137d ago

News Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

147d ago

Scanner Unusual volume (z=13.0)

171d ago